The Inflection Point
Candidate nomination changes everything
-
Marks the shift from discovery to early CMC
-
Scientific promise must translate into clinical readiness
-
Early decisions shape IND success
The Reality
Milligrams are just the start
-
Discovery begins with milligrams
-
Demand escalates quickly to IND-enabling quantities
-
Timelines compress fast
What Early CMC Must Deliver
-
Toxicology material
-
Formulation development
-
Controlled manufacture
-
Clinical drug supply
The Critical Question: Is the discovery route scalable?
Discovery routes favor speed, not scale.
Common challenges include:
-
Costly or limited reagents
-
Inconsistent reaction conditions
-
Inefficient or unreliable purification
Early choices determine long-term feasibility. Discovery routes favor speed, not scale.
A Development-Focused Approach
Build robustness early
Key considerations:
-
Vendor selection
-
Impurity control
-
Yield consistency
-
Process safety and scalability
Beyond Chemistry: Early CMC includes supply chain strategy
A fit-for-purpose supply chain balances:
-
Speed
-
Cost
-
Quality
-
Regulatory foresight
Includes raw material sourcing, supplier qualification, and clear non-GMP to GMP transition points.
Vendor Strategy Matters: Partners influence IND readiness
Evaluate for:
-
Technical capability
-
Capacity and timelines
-
Quality systems
-
Regulatory experience
The Goal
De-risk the path to IND
-
Anticipate future needs
-
Integrate CMC with development strategy
-
Maintain flexibility as data evolves
Result: Smoother IND submissions and stronger regulatory confidence.
Outcome: Quality material delivered on time, minimized technical and regulatory risk, and IND strategies aligned to long-term clinical goals.
How Syner-G Helps
-
Establish structured CMC manifold
-
Design scalable, phase-appropriate processes
-
Manage quality control and process oversight
Bottom Line
Early CMC decisions determine IND readiness long before submission.
Syner-G helps translate discovery science into IND-ready execution with confidence.
